The phase I study will be conducted on a pool of participants in the U.S. who will be offered the opportunity to receive a 30-µg booster of the current vaccine six to 12 months after receiving their initial two-dose regimen. The study will evaluate up to 144 phase I participants in two age cohorts, 18-55 and 65-85 years of age. Participants will be assessed at the time they receive the third dose, then one week and one month after.

The companies are also in discussions with global regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), regarding the clinical study of a variant-specific vaccine with a modified messenger RNA sequence. This new construct would be based on the B.1.351 lineage that was first identified in South Africa. This is in alignment with the FDA's updated guidance regarding emergency use of COVID-19 vaccines to address SARS-CoV-2 variants.

U.S. opts for 100M more doses of Pfizer-BioNTech COVID-19 vaccine
The U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine

Pfizer, BioNTech vaccine neutralizes SARS-CoV-2 variants in vitro
Pfizer and BioNTech has released results from in vitro neutralization studies of blood sera from individuals vaccinated with its COVID-19 vaccine, providing...

Covax to purchase 40M doses of Pfizer, BioNTech COVID-19 vaccine
The Covax global vaccine initiative has reached a deal with Pfizer and BioNTech for 40 million doses of the Pfizer-BioNTech COVID-19 vaccine.

EC authorizes Pfizer, BioNTech COVID-19 vaccine
The European Commission (EC) has granted a conditional marketing authorization to Pfizer and BioNTech for their COVID-19 vaccine.

FDA issues EUA for Pfizer, BioNTech COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. The move comes after...